Reviewing ASLAN PHARMACEU/ADR (ASLN) and Its Competitors

ASLAN PHARMACEU/ADR (NASDAQ: ASLN) is one of 546 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare ASLAN PHARMACEU/ADR to related companies based on the strength of its earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.


This table compares ASLAN PHARMACEU/ADR and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ASLAN PHARMACEU/ADR Competitors -1,776.08% -105.48% -28.48%

Valuation & Earnings

This table compares ASLAN PHARMACEU/ADR and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ASLAN PHARMACEU/ADR $11.55 million -$42.19 million -3.07
ASLAN PHARMACEU/ADR Competitors $2.17 billion $229.91 million -3.77

ASLAN PHARMACEU/ADR’s competitors have higher revenue and earnings than ASLAN PHARMACEU/ADR. ASLAN PHARMACEU/ADR is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

9.4% of ASLAN PHARMACEU/ADR shares are held by institutional investors. Comparatively, 46.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.8% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for ASLAN PHARMACEU/ADR and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ASLAN PHARMACEU/ADR Competitors 4499 12940 27592 991 2.54

ASLAN PHARMACEU/ADR presently has a consensus price target of $10.50, suggesting a potential upside of 144.19%. As a group, “Pharmaceutical preparations” companies have a potential upside of 52.46%. Given ASLAN PHARMACEU/ADR’s stronger consensus rating and higher probable upside, research analysts clearly believe ASLAN PHARMACEU/ADR is more favorable than its competitors.


ASLAN PHARMACEU/ADR beats its competitors on 7 of the 12 factors compared.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Its Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer. It is also conducting a Phase II/III clinical trial of varlitinib for gastric cancer; and testing in a single-arm pivotal clinical trial in biliary tract cancer in China. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL Limited. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit